Metropolitan General Hospital/Healthcare Facilities Operation And Management Single Member S.A

Research at Metropolitan General Hospital focuses on KRAS G12C–mutated advanced non‑small cell lung cancer, aiming to evaluate new targeted agents that may improve patient outcomes.

• KRAS G12C inhibition strategies
• Advanced NSCLC patient selection
• Clinical benefit assessment

These studies seek to bring precision medicine options to individuals with limited treatment alternatives.

The site conducts trials combining checkpoint inhibitors with chemotherapy in PD‑L1‑positive lung cancer, exploring whether dual approaches can extend progression‑free survival.

• PD‑L1 biomarker-driven enrollment
• Combination of immunotherapy and platinum doublet
• Evaluation of disease control rates

Findings aim to refine treatment sequencing for patients with metastatic disease.

At this Greek research center, investigators are advancing cancer care by testing innovative therapies for non‑squamous NSCLC, emphasizing both targeted and immune‑based strategies.

• Integration of molecular profiling
• Multi‑disciplinary trial design
• Collaboration across ten investigators

The ongoing work contributes to the broader European effort to improve outcomes for lung cancer patients.